The trial of Teliso V, an ADC of a c-met antibody and monomethyl auristatin E (microtubule inhibitor), investigated the effectiveness of the drug in several different populations of NSCLC patients to determine which cohort has the most optimal response [72] (Figure 1). Here, MET is linked to non-small cell lung carcinoma.